Starting next year, pharmaceutical companies will have to repay Medicare for any unused amount of drugs that come in single-dose vials.
The mandate was tucked inside the bipartisan infrastructure bill passed last year, and on Thursday Medicare implemented this new provision as part of its broader annual rule that updates physician payments for 2023.